(Q39069273)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Michael Small

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Anna K. Nowak

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Anthony Bosco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Michael J Millward

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Richard A Lake

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

publication date

6 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

5 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

264-272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd.2016.233

5 April 2020

exact match

0 references

cites work

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Immunotherapy and the concept of a clinical cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Financial Toxicity of Cancer Care: It's Time to Intervene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

New challenges in endpoints for drug development in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

How Do Cytotoxic Lymphocytes Kill Cancer Cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

CANCER IMMUNOLOGY. The "cancer immunogram".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Distinct Gene Regulatory Pathways for Human Innate versus Adaptive Lymphoid Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The art of the probable: system control in the adaptive immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Variability and robustness in T cell activation from regulated heterogeneity in protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Intracellular competition for fates in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Activation-induced B cell fates are selected by intracellular stochastic competition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Regulated cell death: signaling and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

C-reactive protein: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Tissue-based class control: the other side of tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

T cell metabolism drives immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Innate immune recognition of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Studying Complex Adaptive Systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Determining the expected variability of immune responses using the cyton model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

T Cell Fate at the Single-Cell Level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

A probabilistic view of immunology: drawing parallels with physics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The flesh-eating bacterium: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Anticipating critical transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Early-warning signals for critical transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Identifying early-warning signals of critical transitions with strong noise by dynamical network markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Immune modulation in cancer with antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Blood mRNA expression profiling predicts survival in patients treated with tremelimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Beyond differential expression: the quest for causal mutations and effector molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Functional characterization of somatic mutations in cancer using network-based inference of protein activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Network biology: understanding the cell's functional organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Interactome networks and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Cross-Tissue Regulatory Gene Networks in Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Error and attack tolerance of complex networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Lethality and centrality in protein networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

From molecular to modular cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Forensic genetics and ethical, legal and social implications beyond the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The genetic landscape of a cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Interferon regulatory factor 7 is a major hub connecting interferon-mediated responses in virus-induced asthma exacerbations in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

A network modeling approach to analysis of the Th2 memory responses underlying human atopic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The transcriptional network for mesenchymal transformation of brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The diminishing role of hubs in dynamical processes on complex networks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

A simple model of global cascades on random networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Influentials, Networks, and Public Opinion Formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

The relative ineffectiveness of criminal network disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Genomic analysis of regulatory network dynamics reveals large topological changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Towards a critical transition theory under different temporal scales and noise strengths.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Early diagnosis of complex diseases by molecular biomarkers, network biomarkers, and dynamical network biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Nature, nurture, or chance: stochastic gene expression and its consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Introducing a New Dimension to Molecular Disease Classifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Mathematical modelling of prostate cancer growth and its application to hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Molecular Imaging of Immunotherapy Targets in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Collective dynamics of 'small-world' networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Dynamic modularity in protein interaction networks predicts breast cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Why the immune system takes its chances with randomness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Rapid eradication of a bulky melanoma mass with one dose of immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Identifying critical transitions and their leading biomolecular networks in complex diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Recovery rates reflect distance to a tipping point in a living system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Dynamical robustness in complex networks: the crucial role of low-degree nodes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Comment on "drug discovery: turning the titanic"

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.233

Transittability of complex networks and its applications to regulatory biomolecular networks

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28057932

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

CTLA-4 blockade in tumor models: an overview of preclinical and translational research

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28057932

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A module map showing conditional activity of expression modules in cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28057932

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD.2016.233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28057932%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference